Benzinga | Jun 15, 2021 10:45AM EDT

Eton Pharmaceuticals Announces FDA Approval Of Rezipres (Ephedrine Hydrochloride Injection); Shares Set To Resume Trade At 11:10 a.m. EDT

Eton Pharmaceuticals, Inc (NASDAQ:ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres(r) (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia.



"We are excited to see the approval of Rezipres, which is now our second FDA-approved ready-to-use hospital injectable product. We believe ready-to-use injectable products provide a compelling benefit to hospitals and reduce the need for hospitals to rely on unapproved compounded products," said Sean Brynjelsen, CEO of Eton Pharmaceuticals. "This innovative sulfite-free formulation has been successfully sold in Europe for years, and we are excited to make it available to U.S. patients shortly."